Makary Sails Through Senate Confirmation Hearing for FDA Commissioner

Dr. Martin Makary, President Trump's nominee for FDA Commissioner, appeared before the Senate Health, Education, Labor and Pensions Committee for his confirmation hearing on March 6, 202512.

Makary addressed concerns about recent FDA staffing changes and facility closures, pledging to assess the agency's staffing levels and ensure proper drug review processes1.

The nominee faced questions about the cancellation of a key FDA vaccine advisory committee meeting (VRBPAC). While not committing to reconvene the specific canceled meeting, Makary assured that VRBPAC "will be meeting" if he is confirmed18.

Makary expressed support for expediting generic and biosimilar drug approvals to help lower prescription drug costs18.

The nominee committed to reviewing the FDA's ethics policies, citing potential conflicts of interest in advisory committees18.

Makary emphasized his intention to follow scientific data and processes in decision-making, particularly when questioned about controversial topics like abortion medication2.

Analysts view Makary's nomination positively for the rare disease space, given his support for accelerated approvals and openness to customizing regulatory pathways8.

The hearing was described as "breezy," suggesting Makary is likely to be confirmed as the next FDA Commissioner5.

Sources:

1. https://www.fiercepharma.com/pharma/fda-commissioner-nominee-martin-makary-pressed-cancelled-vaccine-advisory-meetings-senate

2. https://www.youtube.com/watch?v=krJLRRW-lnk

5. https://endpts.com/channel/pharma/

8. https://www.biospace.com/policy/makary-shows-soft-support-for-fda-vaccines-committee-at-confirmation-hearing